Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

27.42 +1.02 (+3.86%)
Streaming Delayed Price Updated: 10:46 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,507
Open 26.60
Bid (Size) 27.37 (200)
Ask (Size) 27.48 (300)
Prev. Close 26.40
Today's Range 26.46 - 27.53
52wk Range 5.485 - 32.64
Shares Outstanding 14,410,143
Dividend Yield 70.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces New Board Member and Board Transition
Appoints accomplished commercial leader Chris Martin to its Board of Directors 
From Oruka Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-3.0%
-3.0%
1 Month
-10.9%
-10.9%
3 Month
+7.3%
+7.3%
6 Month
+94.9%
+94.9%
1 Year
+44.2%
+44.2%

More News

Read More
News headline image
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗
Via Stocktwits
News headline image
AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Via Benzinga
News headline image
Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗
Via Chartmill
News headline image
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Insider Report: The Bulls Can Thank Tech ↗
Via Benzinga
News headline image
Oruka Therapeutics to Present at Multiple November Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stock Market Today: Nasdaq, S&P 500 Futures Rise As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus ↗
Via Benzinga
Topics Stocks
News headline image
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday ↗
Via Benzinga
News headline image
MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗
Via Investor's Business Daily
News headline image
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker ↗
Via Investor's Business Daily
News headline image
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Oruka Therapeutics Announces $180 Million Private Placement
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
From Oruka Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Oruka Therapeutics, Inc. - Common Stock publicly traded?
Yes, Oruka Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Oruka Therapeutics, Inc. - Common Stock trade on?
Oruka Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oruka Therapeutics, Inc. - Common Stock?
The ticker symbol for Oruka Therapeutics, Inc. - Common Stock is ORKA on the Nasdaq Stock Market
What is the current price of Oruka Therapeutics, Inc. - Common Stock?
The current price of Oruka Therapeutics, Inc. - Common Stock is 27.42
When was Oruka Therapeutics, Inc. - Common Stock last traded?
The last trade of Oruka Therapeutics, Inc. - Common Stock was at 01/09/26 10:46 AM ET
What is the market capitalization of Oruka Therapeutics, Inc. - Common Stock?
The market capitalization of Oruka Therapeutics, Inc. - Common Stock is 395.13M
How many shares of Oruka Therapeutics, Inc. - Common Stock are outstanding?
Oruka Therapeutics, Inc. - Common Stock has 395M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.